Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal

Liuqing Yang1, Ye Yang1, Jing Zhang1

  • 1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 100191, Beijing, China.

Insights

Polymer nanoparticles enhance PROTAC delivery for colorectal cancer therapy. These nanoparticles improve tumor penetration and cellular uptake, leading to effective protein degradation and synergistic anti-cancer effects when combined with immune checkpoint inhibitors.

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Oncology

Background:

  • PROteolysis TArgeting Chimeras (PROTACs) show therapeutic promise but face challenges in tissue penetration and cellular internalization.
  • Colorectal cancer (CRC) is often resistant to conventional treatments, including immune checkpoint blockades.

Purpose of the Study:

  • To design pH/cathepsin B sequential responsive nanoparticles (PSRNs) for enhanced intracellular delivery of PROTACs targeting Cyclin-dependent kinase 4 and 6 (CDK4/6).
  • To evaluate the efficacy of PSRNs in a colorectal cancer model and their combination with immune checkpoint inhibitors.

Main Methods:

  • Development of polymer PROTAC-conjugated nanoparticles (PSRNs) with pH and enzyme sensitivity.
  • In vitro and in vivo evaluation of nanoparticle accumulation, penetration, cellular uptake, and PROTAC release in a colorectal cancer model.
  • Assessment of CDK4/6 degradation, PD-L1 expression, regulatory T cell proliferation, and anti-tumor efficacy in combination with α-PD-1 therapy.

Main Results:

  • PSRNs (40 nm) accumulated in tumors and dissociated into unimers (<10 nm) in the acidic tumor microenvironment, enhancing penetration and cellular uptake.
  • Intracellular release of CDK4/6-degrading PROTACs was triggered by cathepsin B cleavage, leading to enhanced target protein degradation in vitro and in vivo.
  • Combination therapy with α-PD-1 significantly improved anti-tumor outcomes in the CT26 tumor model, associated with PD-L1 upregulation and suppressed regulatory T cell proliferation.

Conclusions:

  • Precise intracellular delivery of PROTACs is crucial for enhancing therapeutic efficacy.
  • PSRNs offer a promising strategy for targeted combination therapy in colorectal cancer by improving PROTAC delivery and augmenting immune checkpoint blockade efficacy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...